27224-27-7 Usage
Uses
Used in Pharmaceutical Industry:
1H-Pyrrolo[3,2-b]pyridine-3-acetic acid (8CI, 9CI) is used as a pharmaceutical agent for its anti-inflammatory properties, making it a candidate for the treatment of conditions such as asthma, allergies, and other inflammatory diseases. Its ability to modulate inflammatory responses and alleviate symptoms associated with these conditions positions it as a potential therapeutic option.
Used in Research and Development:
In the field of research and development, 1H-Pyrrolo[3,2-b]pyridine-3-acetic acid (8CI, 9CI) serves as a valuable compound for studying the underlying mechanisms of inflammation and the development of novel anti-inflammatory drugs. Its unique structure and pharmacological profile provide researchers with insights into the design and synthesis of new therapeutic agents with improved efficacy and reduced side effects.
Used in Drug Discovery:
1H-Pyrrolo[3,2-b]pyridine-3-acetic acid (8CI, 9CI) is utilized in drug discovery processes to identify potential lead compounds for the development of new medications. Its pharmacological activities and chemical properties make it a promising starting point for the synthesis of novel anti-inflammatory drugs, which could offer better treatment options for patients suffering from inflammatory conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 27224-27-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,2,2 and 4 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 27224-27:
(7*2)+(6*7)+(5*2)+(4*2)+(3*4)+(2*2)+(1*7)=97
97 % 10 = 7
So 27224-27-7 is a valid CAS Registry Number.
InChI:InChI=1/C9H8N2O2/c12-8(13)4-6-5-11-7-2-1-3-10-9(6)7/h1-3,5,11H,4H2,(H,12,13)
27224-27-7Relevant academic research and scientific papers
MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS
-
Page/Page column 133; 134, (2017/11/04)
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-Ll and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. wherein: A is selected from a bond.
THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE
-
Page/Page column 215, (2012/02/02)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.
